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Clinical feasibility of an advanced
neonatal epidermal
multiparameter continuous
monitoring technology in a large
public maternity hospital
in Nairobi, Kenya
Amy Sarah Ginsburg1*, Sahar Zandi Nia2, Dorothy Chomba3, Millicent Parsimei3,
Dustin Dunsmuir2, Mary Waiyego4, Jesse Coleman5, Roseline Ochieng3, Guohai Zhou6,
William M. Macharia3 & J. Mark Ansermino2
Clinically feasible multiparameter continuous physiological monitoring technologies are needed for
use in resource-constrained African healthcare facilities to allow for early detection of critical events
and timely intervention for major morbidities in high-risk neonates. We conducted a prospective
clinical feasibility study of a novel multiparameter continuous physiological monitoring technology
in neonates at Pumwani Maternity Hospital in Nairobi, Kenya. To assess feasibility, we compared the
performance of Sibel’s Advanced Neonatal Epidermal (ANNE) technology to reference technologies,
including Masimo’s Rad-97 pulse CO-oximeter with capnography technology for heart rate (HR),
respiratory rate (RR), and oxygen saturation (SpO2) measurements and Spengler’s Tempo Easy noncontact infrared thermometer for temperature measurements. We evaluated key performance criteria
such as up-time, clinical event detection performance, and the agreement of measurements compared
to those from the reference technologies in an uncontrolled, real-world setting. Between September
15 and December 15, 2020, we collected and analyzed 503 h of ANNE data from 109 enrolled
neonates. ANNE’s up-time was 42 (11%) h more for HR, 77 (25%) h more for RR, and 6 (2%) h less
for SpO2 compared to the Rad-97. However, ANNE’s ratio of up-time to total attached time was less
than Rad-97’s for HR (0.79 vs 0.86), RR (0.68 vs. 0.79), and SpO2 (0.69 vs 0.86). ANNE demonstrated
adequate performance in identifying high and low HR and RR and high temperature events;
however, showed relatively poor performance for low SpO2 events. The normalized spread of limits of
agreement were 8.4% for HR and 52.2% for RR and the normalized root-mean-square deviation was
4.4% for SpO2. Temperature agreement showed a spread of limits of agreement of 2.8 °C. The a prioriidentified optimal limits were met for HR and temperature but not for RR or SpO2. ANNE was clinically
feasible for HR and temperature but not RR and SpO2 as demonstrated by the technology’s up-time,
clinical event detection performance, and the agreement of measurements compared to those from
the reference technologies.
In high-income countries, multiparameter continuous monitoring technologies can be essential in the clinical
management of high-risk neonates. However, these technologies are frequently unavailable in resource-constrained African settings despite higher neonatal morbidity and mortality1,2. At a large, public, referral hospital
in Nairobi, few neonates had vital signs recorded within the first hour of life, and less than half received heart rate
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(HR; 44%), respiratory rate (RR; 44%) or temperature (46%) recordings on their first day of hospital admission3.
Nursing shortages and high patient workloads at six hospitals in Nairobi county have been associated with
missed vital signs monitoring and other nursing tasks for sick neonates4. Neonatal multiparameter continuous
monitoring technologies could facilitate and improve quality of care by expanding nurses’ capacities to reliably
and efficiently monitor more neonates. Neonatal innovations appropriate for use in resource-constrained health
facilities are needed to allow for early detection of critical events and timely intervention for major morbidities5,6.
Sibel’s Advanced Neonatal Epidermal (ANNE) wireless, multiparameter, continuous monitoring technology
includes two neonatal-sized, non-invasive, adhesive skin sensors attached directly to the skin surface that are
capable of continuously measuring and recording HR, RR, oxygen saturation ( SpO2), and skin surface temperature (Supplementary Fig. S1). Up to 30 h of data can be stored within the sensor and transmitted wirelessly to
a central database supported by customized software. The projected cost of commercial acquisition of Sibel’s
reusable and rechargeable technology is about $40USD with an additional $0.20USD per unit for adhesives/
consumables lasting 24 to 72 h. In a previous clinical trial of neonates in Kenya, we evaluated the accuracy of
ANNE to measure HR, RR, S pO2, and temperature when compared to verified reference t echnologies7. We also
completed qualitative assessments of the feasibility, usability, and acceptability among healthcare personnel and
caregivers by conducting in-depth interviews and o
 bservations8,9.
Novel medical technologies may compare favorably to established reference technologies in more controlled
research settings; however, also important to ascertain is their clinical feasibility in uncontrolled, real-world
settings. If clinical feasibility performance is not evaluated and the findings incorporated during technology
development and refinement, a novel medical technology’s adoption, uptake, scale-up, and use in clinical practice
may be impacted. Thus, in this study we evaluated key performance criteria such as up-time (periods of adequate
signal quality), clinical event detection performance, and the agreement of measurements compared to those
from the reference technologies in an uncontrolled, real-world setting.

Methods

Study design and participants. We conducted a prospective, observational, clinical feasibility study of

ANNE at Pumwani Maternity Hospital (PMH) in Nairobi, Kenya, the largest referral public maternity hospital
in sub-Saharan Africa. PMH has no neonatal intensive care unit. Caregivers of neonates delivered at or admitted to PMH were approached by trained study staff who obtained written informed consent and assessed the
neonate for study eligibility based on the results of the medical history, clinical examination, and appropriate
understanding of the study by the caregiver (Table 1). Carried out in accordance with the Declaration of Helsinki
and Guideline for Good Clinical Practice/ International Standards Organization (ISO) 14155 to ensure accurate,
reliable, and consistent data collection, the study protocol was approved by Western Institutional Review Board
(20191102), Aga Khan University Nairobi Research Ethics Committee (2019/REC-02), and Kenya Pharmacy
and Poisons Board (ECCT/19/05/02) and registered with ClinicalTrials.gov, NCT0392076110. Effort was made to
ensure study participation did not interfere with or unnecessarily delay clinical care of neonates.

Study procedures. Enrolled neonates received local standard of care while additionally being simultaneously monitored with the ANNE multiparameter, continuous monitoring technology (Sibel Inc. IL, USA),
the Rad-97 pulse CO-oximeter with capnography (Masimo Corporation, USA), and Spengler’s Tempo Easy
non-contact infrared thermometer (SPENGLER HOLTEX Group, Aix-en-Provence, France). The Rad-97 was
selected as a reference technology based on its ability to extract and record high resolution data, perform neonatal capnography and pulse oximetry, and its compact design enabling bedside monitoring. Tempo Easy was
chosen as a reference technology for temperature monitoring due to its in-country availability. HR, RR, and
SpO2 data were collected in real-time for a minimum of one hour from ANNE and Rad-97 and temperature data
via hourly spot checks with the Tempo Easy technology. The total opportunity for attaching the technologies was
similar. Up-time, clinical event detection performance, and HR, RR, S pO2, and temperature measurements data
were collected by ANNE and the reference technologies (Table 1). For temperature, readings from ANNE’s chest
sensor were compared to Tempo Easy’s skin temperature readings from the forehead.
Outcomes. To ensure objective measures of clinical feasibility, study outcomes included comparisons
between the ANNE and reference technologies’ total time attached and up-time, and event detection of high and
low HR and RR events, low S pO2 events, and high temperature events. In addition, we evaluated the agreement
between HR, RR, SpO2, and temperature measurements in a real-world setting (Table 1).
Data processing and analysis. The total number of minutes the sensors were attached and the up-time

for each technology were calculated. We assessed the quality of the measurements from the ANNE and reference technologies, and designated periods of adequate signal quality data as up-time (Table 1). For ANNE, we
obtained HR, RR, and SpO2 measurements with their corresponding proprietary signal quality index every
second. Raw data collected in real-time was retrieved from the Rad-97 with a custom Android application.
Data were parsed in C (Dennis Ritchie & Bell Labs, USA) to obtain plethysmograph waveform and plethysmograph quality index (PO-SQI) data at 62.5 Hz (Hz), and capnography (carbon dioxide ( CO2)) waveform data
at approximately 20 Hz. CO2 waveform data were analyzed using a breath detection algorithm developed in
MATLAB (Math Works, USA) based on adaptive pulse segmentation11. We obtained HR and RR from intra-beat
and breath duration intervals, respectively. A custom algorithm based on capnography features was utilized to
determine the capnography quality index ( CO2-SQI). SpO2 values were calculated by the Rad-97 at 1 Hz, and 8-s
medians were used in the analysis. To standardize event detection, upper limits for HR and RR were individualized for each neonate and were calculated for HR to be 20% and for RR to be 15% greater than their respective
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Eligibility criteria

Inclusion

Neonate with corrected age of < 28 days requiring admission to the
neonatal ward, the post-natal ward, or the neonatal high dependency
unit at Pumwani Maternity Hospital for prematurity or other clinical
indication(s) based on the attending physician’s assessment
Caregiver(s) willing and able to provide informed consent and available for follow-up for the duration of the study

Exclusion

Receiving continuous positive airway pressure or mechanical ventilation
Skin abnormalities in the nasopharynx and/or oropharynx
Contraindication to skin sensor application
Known arrhythmia
Congenital abnormality requiring major surgical intervention
Any medical or psychosocial condition or circumstance that would
interfere with study conduct or for which study participation could
put the neonate’s health at risk

Study endpoints
Up-time duration of ANNE compared to the reference technologies
Diagnostic performance of ANNE compared to the reference technologies for clinical event detection including sensitivity, specificity, positive predictive value, negative predictive value, and ratio of false negative-to-false positive events
Agreement between ANNE and the reference technologies for heart rate (HR), respiratory rate (RR), oxygen saturation ( SpO2), and temperature
Study definitions
Total time attached

Measured in minutes as non-zero values recorded by the technology
starting 10 min after technology placement and 5 min before disconnection; the 5-min periods before temporary removal and after reconnection to ANNE and the reference technologies were also excluded

Up-time

Measured in minutes as the total time the sensor was attached that
met the a priori-identified signal quality limits for each technology

Signal quality

HR and SpO2
ANNE—for every second, we evaluated the preceding 59 s in addition
to the current second to ensure that all 60 (100%) seconds > 0
Rad-97—for every second, we evaluated the preceding 59 s in addition to the current second to ensure that at least 30 (50%) seconds
demonstrated a signal quality index (Masimo SQI) > 150
RR
ANNE—for every second, we evaluated the preceding 59 s in addition
to the current second to ensure that all 60 (100%) seconds > 0
Rad-97—for every second, we evaluated the preceding 59 s in addition to the current second to ensure that at least 30 (50%) seconds
demonstrated no capnography exceptions, indicating low RR quality,
and a capnography quality score ≥ 2
Temperature
ANNE—all temperatures > 0
Spengler’s technology—all temperature spot checks

Event second

Any second that contains a high or low HR or RR event (a value
above or below the thresholds) for either ANNE or Rad-97

Event window

A 10-min window centered from 5 min before to 5 min after the
first event second noted by the reference technology; no overlapping
windows are allowed, so event seconds less than 5 min from the end
of the previous event window result in the new event window starting
immediately following the previous window

True positive event

A reference technology event window containing at least 1 event
second identified by ANNE

False negative event

A reference technology event window containing no event seconds
recorded by ANNE

False positive event

An event recorded by ANNE outside all reference technology’s event
windows

True negative event

Any 10-min window with no events recorded by either ANNE or the
reference technology

Clinically significant event

Any false negative or false positive event that would likely require a
clinician to institute a change in clinical practice

Table 1.  Study eligibility criteria, endpoints, and definitions.

baseline values (based on a review of historical data) once the neonate was settled (approximately 15 min after
monitoring was started) but no less than 140 beats/minute for HR and 40 breaths/minute for RR. For all neonates, an upper limit temperature of 37.5 °C was used. Lower limits were static with values of 80 beats/minute for
HR, 15 breaths/minute for RR, and 90% for S pO2 based on the normal physiological range. To identify clinical
events, Sibel provided a software parser that processed all of their monitoring data and provided event detection
in pseudo- real-time that was finalized prior to data collection. Reference technology data were processed following data collection with a custom algorithm to identify events.
For overlapping periods of up-time from ANNE and Rad-97, clinical events were detected by examining
the previous minute of data for both technologies. An event was identified if the one-minute median and the
most recent ten-second median both met adequate signal quality and exceeded the threshold for upper or lower
alarm values for HR, RR, S pO2, or temperature. Using a custom algorithm, events were aggregated from the
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Heart rate
Mean up-time per neonate in hours [range]

Respiratory rate

Oxygen saturation

ANNE

Rad-97

ANNE

Rad-97

ANNE

Rad-97

3.6 [0, 7.3]

3.3 [1.2, 5.7]

3.1 [0, 6.1]

2.4 [0, 4.3]

3.2 [0, 6.1]

3.3 [1.2, 5.7]

Table 2.  Mean up-time per neonate.

technologies into ten-minute windows categorized as true positive, false negative, false positive, or true negative
for high and low HR and RR and low S pO2 for each variable (Table 1)12. A panel of trained neonatologists and
senior neonatology fellows conducted a manual adjudication of algorithmically-identified false negative and
false positive events to identify those that were clinically significant (Table 1). For HR and RR, all false negative
and false positive events that were greater than ten beats per minute for greater than two minutes were submitted for adjudication. For S pO2, all false negative and false positive events that had a difference greater than 4%
between ANNE and Rad-97 for greater than two minutes were submitted for adjudication. Adjudication was
not conducted for temperature monitoring due to a low number of events. Adjudication packages consisting of
visualizations of selected false negative and false positive HR, RR, and S pO2 events and adjudication checklists
were developed and provided to the panel of adjudicators (Supplementary Fig. S2). All false negative and false
positive events were independently evaluated by two adjudicators and a third adjudicator reconciled the results
if there was disagreement. To evaluate ANNE’s event detection, confusion matrices were generated and performance parameters including sensitivity, specificity, positive predictive value (PPV), negative predictive value
(NPV), and false negative-to-false positive ratio for high and low HR and RR, low S pO2, and high temperature
were calculated for both pre- and post-adjudication results.
We evaluated measurement agreement between ANNE and the reference technologies as the normalized
bias and the normalized spread between the 95% limits of agreement (LOA) calculated by dividing the bias
and spread between the 95% LOA by the overall reference HR, RR, SpO2, or temperature mean value13. We also
calculated the root-mean-square deviation (RMSD) for each comparison. Based on the reference technology
verification phase, acceptable a priori-identified normalized spreads between the 95% upper and lower LOA of
30% were selected for both RR and H
 R14. For S pO2, the adequate a priori-identified limit for RMSD was 4.5%
and the optimal limit was 3.5% based on standards from the International Organization for Standardization15.
For temperature, an adequate a priori-identified limit of 4.5 °C for the LOA was selected based on a literature
review and a formal validation s tudy7. R version 4.0.2 (Vienna, Austria 2020) was used for the data analysis.

Role of the funding source. The funders of the study had no role in the study design, data collection, data
analysis, data interpretation, or writing of the report.

Results

Between September 15 and December 15, 2020, we enrolled 114 neonates, 109 of whom were included for
analysis (Supplementary Fig. S3). Five neonates were excluded due to less than one hour recording duration
with ANNE. Neonates were enrolled from the neonatal ward (101; 92.7%), the postnatal ward (5; 4.6%), and
the neonatal high dependency unit (3; 2.8%). The median estimated age of the 57 males and 52 females was
less than 24 (interquartile range less than 24, 120) h and the gestational age was 39 (range 37, 40) weeks. The
median weight was 3.0 (range 2.5, 3.3) kilograms. Common primary and secondary diagnoses included sepsis
or suspected sepsis (29; 26.6%), respiratory distress syndrome (28; 25.7%), asphyxia (21; 19.3%), prematurity
(17; 15.6%), jaundice (15; 13.8%), and meconium aspiration syndrome (12; 11.0%) (Supplementary Table S4).
No neonates required oxygen or other respiratory support during the study period. No adverse events due to
monitoring were observed and all enrolled neonates remained stable until discharge.

Total time attached and up‑time. ANNE exceeded the reference technology’s total and mean up-times

per neonate for HR and RR, but not for S pO2 (Table 2; Fig. 1). ANNE’s up-time was 42 (11%) h more for HR,
77 (25%) h more for RR, and 6 (2%) h less for S pO2 compared to the Rad-97 (Fig. 1). ANNE’s ratio of up-time
to total attached time was less than Rad-97’s for HR (0.79 vs 0.86), RR (0.68 vs. 0.79), and S pO2 (0.69 vs 0.86).

Event detection. ANNE’s high HR event detection indicated adequate performance parameters based on

sensitivity (100%), specificity (86%), and NPV (100%), but not PPV (31%) (Table 3). ANNE’s high RR event
detection also showed adequate performance as demonstrated by the sensitivity (93%), specificity (86%), NPV
(85%), and PPV (94%). Similarly, ANNE’s low HR and RR event detection signalled adequate performance for
the above parameters with the exception of low PPVs (HR 50%; RR 18%). However, ANNE’s low S pO2 event
detection demonstrated relatively poor performance among most of the above parameters with the exception of
specificity (89%) and PPV (91%). Of note, low SpO2 missed events were not normally distributed between cases,
but rather concentrated among a small number of neonates (Fig. 2). ANNE’s high temperature event detection
performed well across all performance parameters (Table 3).

Event adjudication. Pre- and post-adjudication, there were minimal changes in HR and RR performance
parameters with the exception of PPV which improved by 46% post-adjudication for high HR (Table 3). For
SpO2, a substantial improvement ranging from 9% (PPV) to 49% (sensitivity) was observed across all performance parameters between pre- and post-adjudication of events. Of the 1140 false negative and false positive
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Figure 1.  Total time technology attached and up-time.
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Pre
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Post
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Post

Post

Post

Post

Event
True positive

109

109

4

4

1090

1111

3

3

535

1165

1

–

True negative

1426

1633

1661

1661

463

536

1126

1126

464

514

602

–

False positive

240

33

4

4

76

3

14

14

56

6

6

–

False negative

0

0

0

0

81

60

0

0

743

113

3

–

Statistical summary
Accuracy (%)

87

98

100

100

91

96

99

99

56

93

99

–

Sensitivity (%)

100

100

100

100

93

95

100

100

42

91

25

–

Specificity (%)

86

98

99

99

86

99

99

99

89

99

99

–

PPV (%)

31

77

50

50

94

100

18

18

91

100

14

–

NPV (%)

100

100

100

100

85

90

100

100

38

82

100

–

FN:FP

0

0

0

0

1:0.9

1:0.1

0

0

1:0.1

1:0.1

1:2

–

Table 3.  Clinical event detection. Pre-adjudication (Pre); post-adjudication (Post); positive predictive
value (PPV); negative predictive value (NPV); false negative event to false positive event ratio (FN:FP).
Accuracy = (True positive + True negative)/(True positive + True negative + False negative + False positive);
Sensitivity = True positive/(True positive + False negative); Specificity = True negative/(True negative + False
positive); PPV = True positive/(True positive + False positive); NPV = True negative/(True negative + False
negative).

events, 3 high HR events, 24 high RR events, and 87 low S pO2 events were interpreted as clinically significant
during adjudication.

Agreement. HR agreement showed a normalized spread of LOA of 8.4% (Fig. 3a) and RR agreement showed

a normalized spread of LOA of 52.2% (Fig. 3b). The a priori-identified limit of 30% for the normalized spread of
LOA was met for HR but not RR. S pO2 agreement showed a normalized RMSD of 4.4% (Fig. 3c); the adequate
a priori-identified limit of 4.5% for the RMSD was met for S pO2, but the optimal limit of 3.5% was not met. A
sensitivity analysis removing cases where there were at least 10 missed S pO2 events revealed a minimal reduction
in the RMSD from 4.4 to 4.2% (Supplementary Figure S5). Temperature agreement showed a spread of LOA of
2.8 °C (Fig. 3d) and therefore, met the a priori-identified limit of 4.5 °C.
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Figure 2.  Histogram of oxygen saturation missed events. Missed events were concentrated in select
participants.

Discussion

In an evaluation in a large public maternity hospital in Nairobi, Kenya, we found Sibel’s ANNE to be clinically
feasible for some measurement parameters (HR and temperature) but not others (RR and S pO2) as demonstrated
by the technology’s up-time, clinical event detection performance, and the agreement of measurements compared
to those from the reference technologies. Compared to Rad-97’s wired and more invasive technology, wireless
ANNE’s up-time was longer because ANNE could continue to monitor the neonate during feeding and kangaroo
mother care. However, while HR and temperature event detection were optimal and RR event detection was
acceptable, SpO2 event detection was not acceptable. Adjudication established that ANNE incorrectly detected
RR and S pO2 artifacts as clinically significant events during periods of noise, yielding many false positive high
RR and low S pO2 events. Agreement of neonatal measurements between ANNE and the verified reference
technologies showed that HR and temperature measurements met the a priori-identified optimal limits, RR
measurements did not, and S pO2 measurements met the adequate but not the optimal a priori-identified limits
in both the original and sensitivity analyses.
Compared to the findings from a more controlled clinical trial at a better-resourced hospital with a neonatal intensive care unit, there was significant degradation in RR and SpO2 agreement in this real-world clinical
environment, limiting the clinical feasibility of ANNE to assess these measurements in routine practice7. RR
agreement degradation may have been due to imprecise sensor placement and/or inadequate skin adherence.
The low SpO2 missed events were concentrated among a small number of neonates, most likely due to motion
artifacts, low perfusion states, and/or inadequate application of the ANNE sensors in individual neonates.
Reliable SpO2 measurement and monitoring can be challenging in smaller neonates and those with darker skin
pigmentation. Motion artifacts among neonates induce many false alarms, which in turn can cause additional
workload for healthcare providers and stress for the neonates and their caregivers as well as potentially impair
response times in real critical situations16–18. Low perfusion states and variations in breathing can be common
in neonates and can degrade pulse oximeter p
 erformance19–21. Smaller neonatal finger size and a correspondingly smaller pulsatile signal detected by the pulse oximeter sensor may also compromise p
 erformance22–24. As
melanin is a secondary absorber of near-infrared light, darker skin pigmentation may impact pulse oximeter
performance and a ccuracy25,26.
In two large cohorts of adults, Black patients had almost three times the frequency of occult hypoxemia
undetected by pulse oximetry compared to White patients27. However, in a small infant study, no evidence
of systematic bias in pulse oximetry measurement based on skin pigmentation was found in 36 patients with
hypoxemia28. In another study of 294 neonates less than 32 weeks gestation, SpO2 overestimation measured
by mean bias was 2.4-fold greater among Black preterm neonates and resulted in greater occult hypoxemia26.
Validation studies of new medical technologies need to include diverse p
 opulations29.
Previous studies have evaluated the accuracy of single parameter monitoring technologies under controlled
experimental conditions or have performed qualitative feasibility assessments30,31. In our study, we utilized a
comprehensive and integrated approach that included real-world accuracy evaluations combined with performance metrics such as up-time and event detection that are often important in critical clinical situations. Solely
focusing on the accuracy may not appropriately reflect the poor performance in event detection in individual
cases. Regulatory approval typically requires controlled experiments looking at agreement or accuracy but does
not consider real-world applications or event detection. Performing well in a controlled accuracy evaluation,
while important, does not necessarily ensure a medical technology will perform well in clinical practice and
have real-world impact.
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Figure 3.  Bland–Altman plots of measured (a) heart rate (HR), (b) respiratory rate (RR), (c) oxygen saturation
(SpO2), and (d) temperature as measured by ANNE and the reference technologies. Colors indicate which
participant neonate is associated with the measurement pair.
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Figure 3.  (continued)
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Limitations to our evaluation, analyses, and adjudication included the relatively arbitrary a priori signal
quality limits we selected to mitigate confusion that could have arisen if poor quality signals were used for event
detection. To ensure comparable event detection, we evaluated the technologies in real-time even though we
analyzed the data later. Limiting the generalizability of our evaluation was a relatively healthy study population with few critically ill neonates included and infrequent life-threatening events recorded. While comparing ANNE’s electrocardiogram-derived HR to Rad-97’s photoplethysmogram-derived HR may contribute to
increased uncertainty in these comparisons, HR estimation has been shown to be well preserved from the
photoplethysmogram32. We limited our comparison to the detection of low RR and did not evaluate the detection of apnea since ANNE did not have an apnea algorithm. Overall, clinically significant events were relatively
uncommon despite the sustained duration of monitoring, and we did not permit ANNE or the reference technologies to generate alarms that may have impacted clinical outcomes. ANNE would benefit from being further
evaluated in different populations (e.g., preterm and more critically ill neonates) and settings with assessment
of clinical outcomes and/or impact. To be clinically feasible, safe, and effective in improving quality of neonatal
care, a monitoring technology needs to avoid excessive alarms (and alarm fatigue) resulting from false positive
events and to suppress transient artifacts without missing clinically significant true positive events. Typically,
this could be accomplished by employing certain false alarm limiting strategies such as an appropriate delay
before alarm generation. Exploring threshold and adaptive alerts provided by the technology, assessing barriers
and facilitators to adoption and use, and conducting costing studies will be key to ANNE’s development and if
successful, to its uptake and scale-up.
There were additional technology constraints. ANNE experienced intermittent difficulty turning on after
more than one week without use and a software bug resulted in some corruption of data and data loss. The wireless Bluetooth technology required daily charging of batteries, with regular checks to mitigate against data loss.
Furthermore, the battery life degraded over the study period. Another potential limitation of wireless technology
may include electrical interference from other devices in the vicinity; however, this was not experienced in this
study. For temperature measurement, both ANNE and Tempo Easy’s technology measured skin surface temperature, which is dependent on the environmental room temperature, and thus, may not be accurate in detecting
hypothermia. The measurement of core temperature is critical in neonates due to their large surface area which
accelerates heat loss. Hypothermia is a common presenting sign for other severe physiological disturbances
such as sepsis. For this reason, we did not set an event threshold for low temperature, but we acknowledge that
monitoring core body temperature in neonates may be critically important. The Rad-97 also had constraints,
including that it was relatively heavy with cumbersome sensory cables and cords, and prone to overheating when
the air vent was covered. Furthermore, its sensors were not reusable and the nasal cannula was more frequently
removed, limiting the technology’s up-time.
Despite the limitations and technology constraints, the study results from this and a previous accuracy evaluation in Kenya indicate that ANNE appears to be clinically feasible for wirelessly monitoring HR and temperature
but not RR and S pO2 when compared to the more invasive Rad-97 reference t echnology7. Studies of monitoring
technologies in neonates have largely been limited to high-income countries and would benefit from diversification of study populations. Established methods for continuous monitoring exist, but factors such as invasiveness,
time-consuming application, and high cost have contributed to feasibility concerns in resource-constrained
settings. Novel neonatal multiparameter continuous monitoring technologies such as ANNE may be able to
address these concerns; however, more work needs to be done regarding ANNE’s RR and S pO2 measurements.

Data availability

Access to data will be provided to researchers subject to submission of a research proposal and signing a Data
Use Agreement. Interested researchers can request access to the data at https://doi.org/1 0.25934/PR00007550 by
creating a Vivli account and submitting a request. Data will be available from September 2022.
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